Delivery Order SPE2DB24D8002-SPE2DB25FJMUC
Award Date
11/26/24
Potential Completion Date
11/27/24
Potential Value
$8.9K
Federal Agency
Defense Logistics Agency
Awardee
Dakota Drug, Inc.
Ultimate Awardee
Not listed
NAICS Category
424210 - Drugs and Druggists' Sundries Merchant Wholesalers
PSC Category
6505 - Drugs And Biologicals
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Anoka, MN, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a federal contract award from the Defense Logistics Agency (DLA) Troop Support Medical division to Dakota Drug, Inc., a self-certified small disadvantaged business. The $11,049.12 firm fixed-price delivery order contract is for the supply of DUPIXENT 300 MG/2 ML PEN 2ML medical products. This award is part of Dakota Drug's existing $999,999,999.00 Indefinite Delivery Contract (IDC) with the DLA, SPE2DB24D8001, under the ECAT Generation V Program. The contract has a period of...
This federal contract award was issued by the Defense Logistics Agency (DLA), a defense agency, to Dakota Drug, Inc., a self-certified small disadvantaged business. The $1,867.25 firm fixed-price delivery order is for the supply of DUPIXENT 300 MG/2 ML SYRINGE 2ML, a pharmaceutical product. The award is not associated with a set-aside program. Dakota Drug, Inc. holds a significant $999,999,999.00 Indefinite Delivery Contract (IDC) with the DLA as part of the DLA Troop Support Medical's ECAT...
This federal contract award to Dakota Drug, Inc., a self-certified small disadvantaged business, was issued by the Defense Logistics Agency (DLA) for the delivery of DUPIXENT 300 MG/2 ML PEN 2ML, a pharmaceutical product. The award is a Firm Fixed Price Delivery Order contract with a ceiling value of $5,161.66 and a performance period extending through February 21, 2025. Dakota Drug, Inc. holds a significant single-award Indefinite Delivery Contract (IDC) with the DLA, identified as...
This federal contract award, identified as SPE2DB24D8001 and SPE2DB25FKZDB, was made by the Defense Logistics Agency (DLA) to Dakota Drug, Inc., a self-certified small disadvantaged business. The $5,784.90 firm fixed-price delivery order is for the provision of DUPIXENT 300 MG/2 ML PEN 2ML, a pharmaceutical product. The award is part of Dakota Drug, Inc.'s larger Indefinite Delivery Contract (IDC) with the DLA, valued at $999,999,999.00, which allows the company to supply a comprehensive range...
This is a federal contract award by the Defense Logistics Agency (DLA) to Dakota Drug, Inc., a self-certified small disadvantaged business. The $4,722.06 Firm Fixed Price Delivery Order contract is for the supply of DUPIXENT 300 MG/2 ML PEN 2ML pharmaceutical products. The contract has an ultimate completion date of February 5, 2025. Dakota Drug, Inc. holds a significant single-award Indefinite Delivery Contract (IDC) with the DLA, valued at $999,999,999.00, which allows the company to provide a...
This is a federal contract award from the Defense Logistics Agency (DLA) to Dakota Drug, Inc., a self-certified small disadvantaged business. The $7,274.15 firm fixed-price delivery order is for the pharmaceutical product DUPIXENT 300 MG/2 ML SYRINGE 2ML, with a period of performance through February 1, 2024. Dakota Drug, Inc. holds a $999,999,999.00 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical division, as part of the ECAT Generation V Program, which allows the...
The Defense Logistics Agency (DLA) awarded a $5,601.75 firm fixed-price delivery order contract to Dakota Drug, Inc., a self-certified small disadvantaged business, for the provision of DUPIXENT 300 MG/2 ML PEN 2ML pharmaceutical products. This contract, which does not have a set-aside designation, is part of a larger $999,999,999.00 Indefinite Delivery Contract (IDC) that Dakota Drug, Inc. holds with the DLA Troop Support Medical's ECAT Generation V Program, which procures commercial medical...
This federal contract award SPE2DX15D8003|SPE2DX24F7D9E was issued by the Defense Logistics Agency (DLA) to Dakota Drug, Inc., a self-certified small disadvantaged business, for the delivery of DUPIXENT 300 MG/2 ML PEN 2ML pharmaceutical products. The firm-fixed-price contract has a ceiling value of $5,788.47 and an ultimate completion date of May 24, 2024. Dakota Drug, Inc. is a key supplier for the DLA Troop Support Medical division, holding a $999,999,999.00 Indefinite Delivery Contract (IDC)...
This federal contract award, identified as SPE2DX15D8003|SPE2DX24F7D7Z, was issued by the Defense Logistics Agency (DLA) to Dakota Drug, Inc., a self-certified small disadvantaged business. The contract, valued at $5,710.06, is for the delivery of the pharmaceutical product DUPIXENT 300 MG/2 ML PEN 2ML. The contract has a period of performance through May 14, 2024 and is a firm fixed-price delivery order. Dakota Drug, Inc. is a key supplier for the DLA Troop Support Medical division, providing a...
This is a federal contract award to Dakota Drug, Inc., a self-certified small disadvantaged business located in Anoka, Minnesota. The $2,238.61 firm fixed-price delivery order was awarded by the Defense Logistics Agency (DLA) and is not set-aside. It provides for the delivery of DUPIXENT 300 MG/2 ML PEN 2ML, a pharmaceutical product, to support U.S. Armed Forces medical operations. Dakota Drug, Inc. holds a significant single-award Indefinite Delivery Contract (IDC) with the DLA, valued at...